Academia and Research Centres (Biopharmaceutical Products)

Danish pharmaceutical giant Novo Nordisk will be opening an AI-based research facility in the heart of London to advance drug discovery operations.

Novo Nordisk will invest 15.9 billion Danish kroner into the expansion of their existing API manufacturing facility.

Novavax, developers behind the Matrix-M adjuvant, have entered into an agreement with the Bill and Melinda Gates Medical Research Institute to provide the adjuvant in preclinical vaccine research.

NextPharma has completed their acquisition of a Norway-based manufacturing site, specialising in chewable tablet technologies for calcium/vitamin D3 from pharmaceutical giant Takeda.

In collaboration with Thermo Fisher Scientific, UCSF has opened a new manufacturing site aimed at accelerating advanced cell and gene therapies for cancer, rare diseases, and other illnesses.

In an effort to protect against potential future global health emergencies, the government of the UK and Moderna have cemented a 10-year partnership for vaccine manufacturing and research.

Purolite, an Ecolab company, marked the opening of a new Customer Experience Centre featuring hands-on interactive and educational displays, showcasing the company’s expanded bioprocessing solutions.

BioNTech, co-developers of one of the first mRNA COVID-19 vaccines, have signed an agreement to create manufacturing hubs in and around the Australian Victoria state in a bid to increase the country’s mRNA manufacturing abilities.

Merck opens their latest commercial manufacturing facility in Martillac, France, boasting rapid development and commercialisation of drug products with streamlined processes and state-of-the-art technology.

The latest episode in the CPHI Podcast Series explores how startups are driving innovation by taking high-risk approaches and doing business with greater agility.

UK-based CRO Quanticate is set to partner with Cancer Research UK for the launch of the DETERMINE study focused on testing a range of existing and approved drugs and therapies on rare cancers.

The malaria vaccine R21/Matrix-M, developed by researchers at Oxford University, has produced encouraging new data for the global effort against the mosquito-borne disease.